- The Benefits of Green Tea for Cancer and Leukemia By : Chris Galloway
Green tea has long had many health benefits associated with it and its curative properties have been used in Chinese medicine for thousands of years. - Leukemia and What Online Writers Can Do to Help By : Lance Winslow
They say that the pen is mightier than the sword and indeed it is. Now then is the keyboard and word processor mightier than cancer? - Benzene Exposure Can Lead to Acute Myleogenous Leukemia By : Gary Plunkett
Over the past 60 years, oil workers have been known to have an alarming degree of leukemia diagnoses. Although it had often been cited as being a genetic problem, recent studies have shown that even minor exposure to this chemical dramatically increases the chance of contracting any of a number of cancers. - Soft Drink Alert: Dangers of Benzene By : Brenda Skidmore
Losing weight is a real major health concern for at least two-thirds of the American population. Many adults and children drink themselves into being overweight or obesity. - Free Monophonic Ringtones By : Thomas Morva
Cell phones are used for communication. But more and more, personalized services and the entertainment quotient involved with cell phones has grown in importance. - Cancer Therapies Right On Target By : Stacey Moore
Cancer has always been synonymous with loss and fear. With today's new advancements in prevention, detection and treatment, a diagnosis of cancer no longer necessarily means facing a terminal disease. Rather, as new advances provide more treatment options, cancer increasingly takes on the shape of a chronic condition. - Allos Therapeutics Receives Special Protocol Assessment For Pivotal Phase 2 Study By : Medical News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment process (SPA) on the design of a pivotal Phase 2 trial of the company's novel, next generation antifolate PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). - Thrombosis In Children With Leukaemia By : Medical News
Helping researchers and doctors to better understand and face, by the most appropriate tools, a serious complication that may occur in children affected by acute lymphoblastic leukemia (ALL): thrombosis, i.e. blood vessel occlusion due to blood clots, the most common cause for heart attack, pulmonary embolism and other cardiovascular diseases. - Thrombosis In Children With Leukaemia By : Medical News
Helping researchers and doctors to better understand and face, by the most appropriate tools, a serious complication that may occur in children affected by acute lymphoblastic leukemia (ALL): thrombosis, i.e. blood vessel occlusion due to blood clots, the most common cause for heart attack, pulmonary embolism and other cardiovascular diseases. - New Targeted Therapy May Fight Leukemia By : Medical News
Scientists have identified a new drug that targets a cancer-promoting protein and may work against acute myeloid leukemia in a mouse model. - Loosen Up, DNA: Leukemia Gene Changes Genetic Packaging By : Medical News
A signaling system involved in many forms of leukemia and lymphoma is more powerful than scientists have thought, exerting control over our genes by affecting whole swaths of chromosomes in global fashion, according to a paper in the September issue of Nature Genetics and appearing online in August. - Cell Therapeutics, Inc. (CTI) Announces Encouraging Pixantrone Phase III Interim Data By : Medical News
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) reported today that based on preliminary encouraging confirmed and unconfirmed complete response (CR/uCR) rates observed among the first 40 patients with aggressive non-Hodgkin's lymphoma (NHL) treated in its randomized phase III trial of pixantrone, the Data Monitoring Committee recommended that the study continue. The Company plans to conduct a second interim analysis early next year. - FDA Grants Priority Review To VELCADE(R) (Bortezomib) For Injection For Treatment Of Relapsed By : Medical News
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation to its supplemental new drug application (sNDA) for VELCADE for the treatment of relapsed mantle cell lymphoma (MCL), an aggressive, incurable subtype of non-Hodgkin's lymphoma (NHL) for which there is no current standard of care. - Children's Leukemia Treatment Affected By Medication Errors By : Medical News
Almost one in five children treated for acute lymphoblastic leukemia (ALL) does not receive the appropriate chemotherapy regimen due to medication errors, according to a new study. Published in the September 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that 10 percent of chemotherapeutic medications for outpatients were prescribed or administered incorrectly. - Agreement Reached On Teen's Cancer Treatment By : Medical News
Starchild Abraham Cherrix, 16, has Hodgkins' Disease, a cancer of the lymphatic system - he was diagnosed a year ago. A three month course of chemotherapy debilitated him so much that he refused to accept a second, more intensive course of chemotherapy earlier on this year when the cancer came back. His doctors had recommended that he receive this second round of treatment. - Hodgkins Lymphoma By : Alison Cole
A type of lymphoma, not as common as Non-Hodgkin's Lymphoma, is Hodgkin’s disease or Hodgkin’s Lymphoma, which is characterized by malignant growths of cells in the lymphoid system. Thomas Hodgkin, who discovered this disease in 1832, was an English scholar who worked at the Guy’s Hospital in England. - Lymphoma - A Parent's Journey of Life and Death seen Through the Eyes of A Child By : Janice Karp
When A parent is diganosed with an incurable cancer the journey is long and hard. The child must now become the parent relying on what they were taught to take control of the situation. This is a story of role reversal as well as a story of acceptance of choice. - Genta Revises Notice Of Special Protocol Assessment For Confirmatory Trial Of Genasense(R) By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that the Company has received communication from the Food and Drug Administration (FDA) that FDA has not yet completed its review of the Company's proposal for a confirmatory trial of Genasense(R) (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia. The request for Special Protocol Assessment was submitted in December 2005. - Lymphoma Symptoms By : Alison Cole
One of the most important factors in determining the survival rate or chances for remission of cancer patients is early detection. Some cancers where this is very true include breast cancer and prostate cancer because early detection of the disease makes it easier to treat since the cancer is usually just found in one localized area. With regard to lymphomas, the same principle applies; early detection of lymphomas has been proven to lead to higher survival rates. The key to early detection is an awareness of symptoms that indicate the presence of a lymphoma. Fortunately, research on this topic is extensive and provides a wealth of information that can help people detect the symptoms of lymphoma. - An Introduction To Lymphoma By : Alison Cole
One of the most important organ systems of the human body is the lymphatic or lymphoid system, which is a network of node-like structures located throughout the body. This system helps filter out bacteria and plays an important role in fighting diseases. However, just like any other organ system in the body, it is also vulnerable to developing cancers. Unfortunately, cancers that affect the lymphatic system can be dangerous, since lymph nodes are located all throughout the body. And just like leukemia, cancers involving the lymphoid system have the potential to spread. - Non Hodgkins Lymphoma By : Alison Cole
There are two types of lymphomas: Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Lymphoma. Among the two, there are more cases of Non-Hodgkin's Lymphoma among those that suffer from cancer in their lymphoid systems; it encompasses over 29 types of lymphomas. In the United States, the cases of reported Non-Hodgkin's are at least seven times as common as cases of Hodgkin's Lymphoma. - New Surgical Technique Could Help Save The Hips Of Children With Leukemia Suffering From Avascular By : Leukemia News
A new surgical device named the “Hip ToolTM” by its creator, Orthopedic Surgeon Dr. James K. Brannon, could provide an alternative to radical hip replacement surgery for children with leukemia suffering from a debilitating hip condition called osteonecrosis/avascular necrosis (AVN). - Molecular Process Underlying Leukemia Identified By Study By : Leukemia News
New research from the University of North Carolina at Chapel Hill has identified a molecular process in cells that is crucial to the development of two common leukemias. The findings help explain how fundamental cell processes go awry during cancer development and represent a first step toward new, targeted treatments for leukemia. - Hana Biosciences Initiates Marqibo(R) Phase II Clinical Trial in Relapsed By : Health News
Hana Biosciences (NASDAQ:HNAB):
-- Trial Represents First Stage of Registration Program for Targeted Chemotherapy Agent
-- Multinational, Multicenter Phase III Randomized Trial in ALL to Commence before Year-End 2006 - CuraGen And TopoTarget Announce Southwest Oncology Group Opens New Lymphoma Trial With PXD101 By : Leukemia News
CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) today announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. - New Strain Of Mice Mimics Chronic Leukemia And Will Aid Drug Development By : Leukemia News
A study by cancer researchers here reveals that a new strain of mice offers the first real animal model for an incurable form of chronic leukemia and should greatly aid the development of new drugs for the disease. - SGX Pharmaceuticals Discontinues Phase II/III Clinical Trial Of Troxatyl In Third-Line Acute By : Leukemia News
SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) announced today that it has discontinued the Phase II/III clinical trial of Troxatyl(TM) as a third-line treatment for patients suffering from acute myelogenous leukemia (AML), based upon the recommendation of the study's independent data and safety monitoring board (DSMB). The DSMB found that the study response rates were unlikely to provide evidence of a treatment benefit as a third-line treatment for patients with AML. - Allos Therapeutics Initiates Pivotal Phase 2 Study Of PDX In Patients With Peripheral T-cell By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced enrollment of the first patient in PROPEL, a pivotal multi-center Phase 2 study of the Company's unique next generation antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). - Genzyme Begins Phase 3 Pivotal Study Of Clolar(R) In Adult Acute Myelogenous Leukemia By : Leukemia News
Genzyme Corporation (Nasdaq: GENZ) announced today that the first patient has been treated in a new phase 3 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in older patients with acute myelogenous leukemia (AML). This is the first pivotal clinical study of clofarabine in adult patients with AML, and is expected to provide substantial support for expanding the current product label. - Epstein-Barr Virus' Ability To Form And Sustain Tumors, Clue Found By Researchers By : Leukemia News
Researchers at the University of Wisconsin School of Medicine and Public Health (SMPH) have found a viral target that opens the door for the development of drugs to destroy tumors caused by Epstein-Barr virus (EBV). - Combination Of High Dose QUADRAMET(R) And Chemotherapy Shows Promise For Treatment Of High-Risk By : Leukemia News
Cytogen Corporation (Nasdaq: CYTO) today announced the publication of new data relating to the Company's QUADRAMET(R) (samarium Sm-153 lexidronam injection) product. - New Drug Target Might Sidestep Gleevec Resistance, Jefferson Scientists Show By : Leukemia News
Though enormously successful, the leukemia drug Gleevec has some downsides. Recent studies have linked the drug to heart failure in a small number of patients, and drug resistance continues to be a problem. But now, researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a new way to sidestep such resistance. - Autoimmune Conditions Linked To Hodgkin Lymphoma Incidence By : Leukemia News
A personal history of systemic autoimmune disease is associated with an increased risk of Hodgkin lymphoma; a family history of some autoimmune conditions may also be associated with increased risk. - Vaccination Increases Survival In Lymphoma Patients By : Leukemia News
Idiotypic vaccination can increase the survival times of follicular lymphoma patients. - Glivec® Receives Additional EU Approvals For Use In Treating A Rapidly Progressive Form Of Leukemia By : Leukemia News
Novartis has received additional European Union approvals for Glivec® (imatinib) to help patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor. Both are rare and potentially life-threatening diseases with few, if any, approved treatments that have resulted in poor long-term outcomes. - EntreMed Commences MKC-1 Clinical Trial In Leukemia Patients By : Leukemia News
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a Phase 1 study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. - EntreMed Commences MKC-1 Clinical Trial In Leukemia Patients By : Leukemia News
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a Phase 1 study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. The study will be conducted at the University of Texas MD Anderson Cancer Center in Houston, Texas. - An Examination of Non-Hodgkins Lymphoma By : Morgan Hamilton
Cancer is a life-threatening disease that is prevalent in our time. One of which is known as non-Hodgkins lymphoma or NHL. It is a cancer that affects the lymphatic system and develops in the lymphoid tissue, which contain lymphocytes that are found all over the body. - FDA Approves Two New Indications For Rituxan(R) In Patients With Non-Hodgkin's Lymphoma By : Leukemia News
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). - NICE Recommends Rituximab For The First Line Treatment Of Follicular Lymphoma, UK By : Leukemia News
NICE has issued guidance to the NHS in England in Wales recommending rituximab, within its licensed indications, (that is, in combination with cyclophosphamide, vincristine and prednisolone - or CVP) as an option for the treatment of patients with symptomatic stage III and IV follicular lymphoma who have previously been untreated. - Cellgate Initiates Innovative Phase Ib Clinical Study Of Anti-proliferative Agent, CGC-11047 By : Leukemia News
Cellgate Inc., a company developing novel anti-proliferative drugs to combat cancer and other diseases, today announced the initiation of a Phase Ib clinical study of CGC-11047 in patients with advanced solid tumor malignancies or lymphomas. - Allos Therapeutics Receives FDA Fast Track Designation For PDX For The Treatment Of T-cell Lymphoma By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the Company's unique next-generation antifolate PDX (pralatrexate) for the treatment of patients with T-cell lymphoma. - NCCN Updates Chronic Myelogenous Leukemia Guidelines By : Cancer News
The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in OncologyTM for Chronic Myelogenous Leukemia (CML). These changes highlight leading developments in the treatment of CML and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. - Genta Receives Special Protocol Assessment From FDA For Randomized Trial Of Genasense(R) By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that the Company's proposal for a randomized trial of Genasense(R) (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia (CLL) has completed Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). - Journal Of Clinical Oncology Publishes Final Study Results Of VELCADE(R) (Bortezomib) For Injection By : Leukemia News
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the Journal of Clinical Oncology has published the final results of the PINNACLE trial, one of the largest multi-center studies ever done in the setting of relapsed mantle cell lymphoma (MCL). - Three Molecular Triggers Threaten Leukemia Patients By : Leukemia News
The road to better treatment for the most common form of adult leukemia will require blocking multiple molecular pathways that fuel the disease, researchers at The University of Texas M. D. Anderson Cancer Center report in the Oct. 1 edition of the journal Blood. - Cincinnati Children's Researchers Publish Findings On Potential Target For Leukemia Treatment By : Leukemia News
Cincinnati Children's Hospital Medical Center today announced the publication of pioneering research identifying the crucial role and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. The findings, along with other studies, suggest that RhoH GTPase may provide a target for therapeutic intervention in some types of leukemia. - The Leukemia & Lymphoma Society Launches Program To Ease The Return To School For Children By : Leukemia News
Each year approximately 9,000 children and teenagers are diagnosed with cancer in the United States, with leukemia representing more than 30% of these cases. Thanks to research advances, the survival rate for the most common pediatric cancer, acute lymphocytic leukemia (ALL), has improved from a dismal 4 percent in the 1960s to more than 85 percent today. However, for children who survive cancer, the challenges continue long after the treatments are over. - Potential Target For Leukemia Treatment: Cincinnati Children's Researchers Publish Findings By : Leukemia News
Cincinnati Children's Hospital Medical Center today announced the publication of pioneering research identifying the crucial role and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. - Child Leukemia - Generalities, Symptoms and Treatment By : Groshan Fabiola
Leukemia interferes with the body's production of white blood cells. These cells are supposed to fight infections with viruses or bacteria, and when someone has - Chronic Leukemia - A Less Dangerous Cancer, But Harder To Treat By : Groshan Fabiola
Leukemia is a dangerous form of cancer, and it affects thousands of people every year. It affects the white blood cells. The body loses control of the quantity - New Hope For Children When Leukemia Treatment Fails By : Leukemia News
Clinicians at St. Jude Children's Research Hospital have successfully demonstrated an improved technique for blood stem cell transplantations in children that shows promise for those most likely to fail standard treatment for leukemia. - Symptoms of Chronic and Acute Leukemia By : Groshan Fabiola
Discovering leukemia while it is still in an early phase is crucial in its treatment because when the disease advances it starts to spread in the whole body and it's much harder to be treated. - Thousands Of Myeloma Patients Lose Their Last Hope After Not-so-NICE Final Ruling On Velcade, UK By : Leukemia News
Too expensive was the reason given by the National Institute for Health and Clinical Excellence (NICE) today for rejecting a vital treatment for the bone marrow cancer, myeloma, despite it being the only treatment to be licensed for patients in over ten years. - FDA Extends Review Period For Genasense(R) New Drug Application In Chronic Lymphocytic Leukemia By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has extended the review period for the currently pending New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). - Patient Accrual Completed Into Phase 3 Trial Of Genasense(R) In Patients With Acute Myeloid Leukemia By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that target patient accrual has been completed into a randomized Phase 3 trial of Genasense plus chemotherapy in previously untreated patients with acute myeloid leukemia (AML). The trial was conducted by the Cancer and Leukemia Group B (CALGB), the largest U.S. oncology cooperative group, and was sponsored by the National Cancer Institute (NCI). - Berlex Oncology Evaluating Combination Therapy For Common Form Of Non-Hodgkin's Lymphoma By : Leukemia News
Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub- type of non-Hodgkin's lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. - Promising Target For New Atherosclerosis Therapies Linked To Leukemia By : Leukemia News
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging. Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes. - Promising Target For New Atherosclerosis Therapies Linked To Leukemia By : Leukemia News
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging. Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes. - New Analyses From Phase 3 Trial In CLL Identify Relapsed Patients Who Maximally Benefit By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced the presentation of new analyses from the Company's randomized Phase 3 trial of Genasense(R) (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). - Allos Therapeutics Announces Presentation Of Updated Results From Phase 1/2 Trial Of PDX In Patients By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that updated results from a Phase 1/2 study evaluating the Company's novel antifolate PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease have been accepted for presentation at the American Society of Hematology's 48th Annual Meeting, to be held December 9 - 12 in Orlando. - Deakin University Discovery Could Lead To New Leukaemia Treatments By : Leukemia News
Deakin University scientists have identified a protein that could hold the key to new leukaemia treatments. - Updated Safety Analysis Of Allos Therapeutics Phase 1/2 Study Of PDX In Patients With Aggressive By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the presentation of updated safety results from its Phase 1/2 trial of PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. - Cholesterol Screening A Cost-Effective Procedure To Extend Life In Hodgkin's Survivors By : Leukemia News
Hodgkin's lymphoma survivors who have lipid screening every five years to detect high cholesterol will live a half year longer than patients who don't have the screening and the intervention is cost-effective, according to a study presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia. - Value Of 'Helper' Compound In Treating Some Leukemias By : Leukemia News
The abberant Philadelphia chromosome is not a problem local to Philadelphia, but that's where researchers discovered the genetic mutation that's the root cause of some leukemias, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). - Researchers Identify Cells That Make Relapse Inevitable After Treatment For Acute Lymphoblastic By : Leukemia News
Prague, Czech Republic: In "Dr Jekyll and Mr Hyde" Robert Louis Stevenson wrote about the good and evil sides of the same person; now scientists in Australia have discovered that in acute lymphoblastic leukaemia (ALL) there are Dr Jekyll and Mr Hyde cells - "good" and "evil" clones of the same type of ALL cell. - Cholesterol Screening A Cost-effective Procedure To Extend Life In Hodgkin's Disease Survivors By : Leukemia News
Hodgkin's lymphoma survivors who have lipid screening every five years to detect high cholesterol will live a half year longer than patients who don't have the screening and the intervention is cost-effective, according to a study presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia - Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial By : Leukemia News
Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that the Data Monitoring Committee (DMC) completed its prospectively planned interim analysis of a secondary endpoint in the first 233 patients enrolled in the Company's ongoing pivotal, placebo-controlled Phase 3 clinical trial of FavId(R) following Rituxan(R) induction therapy in patients with follicular B- cell non-Hodgkin's lymphoma (NHL) - Vion Pharmaceuticals Reaches Midpoint Of Patient Accrual To Cloretazine(R) (VNP40101M) Phase III By : Leukemia News
Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that it had accrued 210 patients to the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M). The trial is evaluating Cloretazine(R)(VNP40101M) in combination with cytarabine for the treatment of relapsed acute myelogenous leukemia (AML). - Cells Identified That Make Relapse Inevitable In Acute Lymphoblastic Leukemia By : Leukemia News
In "Dr Jekyll and Mr Hyde" Robert Louis Stevenson wrote about the good and evil sides of the same person; now scientists in Australia have discovered that in acute lymphoblastic leukaemia (ALL) there are Dr Jekyll and Mr Hyde cells - "good" and "evil" clones of the same type of ALL cell. - Findings On The Mechanisms That Cause Resistance To Treatment May Lead To Better Targeted Therapies By : Leukemia News
Research to be published in the journal Blood and posted today on the journal's Web site, suggest that defects in the way blood cells process critical messages are what make patients with acute myelogenous leukemia (AML) resistant to therapy. That discovery may suggest new ways to treat patients with AML. - The Leukemia & Lymphoma Society, Ensemble Discovery Corp. Initiate Research Program To Apply By : Leukemia News
Marking the launch of its new initiative to accelerate the development of blood cancer therapies, The Leukemia & Lymphoma Society today announced a collaboration with Ensemble Discovery Corp. of Cambridge, MA. - Targeting Leukemic Stem Cells By BCL-2 Inhibition By : Leukemia News
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers - 'Tribbles' Protein Implicated In Common And Aggressive Form Of Leukemia By : Leukemia News
Researchers at the University of Pennsylvania School of Medicine have identified a new protein associated with acute myelogenous leukemia (AML). Several lines of evidence point to a protein called Tribbles, named after the furry creatures that took over the starship Enterprise in the original Star Trek series. Tribbles was first described in fruit flies. - BioCryst's Fodosine(TM) Granted Orphan Status In Europe By : Leukemia News
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that following the favorable opinion of the European Committee for Orphan Medicinal Products (COMP) - Leukemia By : Steve John Cowan
The most dangerous feature of leukemia is that is attacks the blood which then has access to all of the bodies other organs, including the all brain, heart, kidneys and liver - Scientific Breakthrough In The Screening & Treatment Of Canine Lymphoma Cancer Is A World First By : Leukemia News
Canine lymphoma is one of the most prolific cancers in the dog population. It accounts for more than 20 percent of all cancers and in certain high risk breeds this figure could be considerably higher. - Genzyme Begins Phase 2 Pivotal Study Of Clolar(R) In Adult Acute Myelogenous Leukemia By : Leukemia News
Genzyme Corporation (Nasdaq: GENZ) announced today that it has begun treating patients in a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. - Abbott Introduces CE-Marked DNA Tests In Europe For The Detection Of Chromosomal Abnormalities Assoc By : Leukemia News
Abbott Molecular today announced that it has introduced six CE-marked DNA tests in Europe for use by diagnostic laboratories in identifying chromosomal abnormalities associated with certain forms of leukemia, a cancer of the white blood cells originating in the bone marrow. - New Hope For Patients With Chronic Lymphocytic Leukemia By : Leukemia News
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology. - Favrille To Report Data From Phase 2 And Phase 3 Clinical Trials Of FavId At American Society Of Hem By : Leukemia News
Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that data from its Phase 2 and Phase 3 clinical trials of FavId(R) following Rituxan(R) induction therapy in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) will be reported at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando. - Study Showed Epratuzumab In Combination With Rituximab And Chemotherapy Is Safe, Tolerable, And Acti By : Leukemia News
Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today reported that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) produced promising results. - New Research Helps Patients With Blood Cancers By : Leukemia News
A NHMRC funded study by the International Program of Psycho-Social Health Research (IPP-SHR) is leading the way to ensure that patients diagnosed with a haematological disorder (blood-related cancer) receive access to palliative care services. - Genetic Susceptibility And Inherited Tendencies In The Occurrence And Treatment Of Blood Cancer By : Leukemia News
People who are born with or develop specific genetic mutations may be prone to certain blood cancers, and some inherited genes associated with cancer apparently cluster within families. - Gleevec(R) Demonstrates Highest Five-Year Overall Survival Rate In History Of Treatment For Patients By : Leukemia News
Data published today in the New England Journal of Medicine underpinned Gleevec(R) (imatinib mesylate) tablets as a durable and well-tolerated long-term therapy for newly diagnosed adult patients with a form of blood cancer known as Philadelphia chromosome- positive (Ph+) chronic myeloid leukemia (CML) - FDA Approves VELCADE(R) (Bortezomib) For Injection For Aggressive Form Of Non-Hodgkin's Lymphoma By : Leukemia News
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of VELCADE for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. - Genta Provides Update On Analysis Of Phase 3 Trial Of Genasense(R) In Older Patients With Acute By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) today announced that the Company has been notified of preliminary results from a randomized Phase 3 trial of chemotherapy with or without Genasense(R) (oblimersen sodium) Injection that was conducted in older, previously untreated patients with acute myelogenous leukemia. - Children's Hospital Researcher Leads Multipronged Attack On Infant Leukemia By : Leukemia News
While survival rates for childhood leukemia have dramatically improved over the past 30 years, infants with this blood cancer continue to face difficult odds. Infant leukemia resists treatments such as chemotherapy and stem cell transplants that may be effective in older children, and infants are especially vulnerable to treatment side effects. - The Best Lymphoma Classification By : Groshan Fabiola
Lymphoma is a severe type of cancer which arise from white blood cells called lymphocytes. In addition to this, white blood cells help the body by fighting against bacteria - Different Treatments to Treat Mantle Cell Lymphoma By : Groshan Fabiola
Lymphoma is a serious affection which affects different parts of the body and usually occurs in many forms. One of the most severe form of lymphoma is known as Mantle cell - Aspartame and the Increased Risks of Lymphoma Cancer By : Groshan Fabiola
According to the findings of a recent study conducted by the Cancer Research Center of the European Foundation of Oncology and Environmental Sciences in Bologna, Italy, the frequent use of aspartame considerably increases the risks of developing lymphoma cancers - Ocular Lymphoma – A Major Indicator of Brain Involvement in Patients with Non-Hodgkin's Lymphoma By : Groshan Fabiola
Ocular lymphoma, also referred to as intraocular large cell lymphoma, is a subtype of Non-Hodgkin’s Lymphoma that primarily affects the central nervous system - Types of Lymphoma and Their Characteristics By : Groshan Fabiola
Lymphoma refers to a form of tumor caused by the immune system, involving abnormal activity of lymphocytes, body cells that belong to the lymphatic system. - Tonsil Lymphoma By : Alison Cole
Lymphoma is a type of cancer that originates in lymphocytes, which are cells that circulate in the lymphatic system. When this cancer affects the tonsils that are part of the lymphatic system, then it is termed as tonsil lymphoma. - Lymphoplasmacytic Disorders By : Alison Cole
Lymphoplasmacytic disorder is a disease that affects the lymphoplasmacyte cells that produce monoclonal light chained immunoglobulins, which are part of the immune system. - Childhood Lymphoma By : Alison Cole
The term childhood lymphoma refers to cancers that originate in the body's lymphatic tissues during childhood and include the lymph nodes, thymus, spleen, tonsils, adenoids, and bone marrow, as well as the lymph vessels that attach them. Although there are many types of cancer that eventually spread to parts of the lymphatic system, lymphomas are distinctive because they originate there. Statistics report that there are about 1,700 children below 20 years of age who are diagnosed with lymphoma each year in the United States. Childhood lymphomas are divided into two basic categories, Hodgkin's disease and non-Hodgkin's lymphoma, based on the appearance of their cancerous cells, and is the third most common type of cancer in children. - How To Stop Lymphoma Ruling Your Life By : Jeremy Parker
Being diagnosed with lymphoma will be incredibly stressful and when treatment starts it may be that you are at the hospital five days a week for up to eight weeks at a time. Obviously this is going to put immense pressure on both you and your family and so the- - Treating Non-Hodgkin lymphoma By : Groshan Fabiola
Until now, patients suffering of Non-Hodgkin lymphoma were treated with chemotherapy and radiation. In some of the cases the treatment was useful but in most patients treatment was very toxic and did not lead to a cure - Lymphoma: Who is Susceptible? By : Jeremy Parker
Lymphoma, as with virtually every other form of cancer, can strike anybody at any time during their life however some groups are more susceptible to the disease than others. Studies around the world have shown that age, gender and geographical location affect whether - General aspects of Mantle Cell Lymphoma By : Groshan Fabiola
Mantle cell lymphoma (MCL) takes part to a group of cancers which affect the lymphatic system. This diseases are known as non-Hodgkin's lymphomas. The immune system
|
